Sinder Benjamin P, Lloyd William R, Salemi Joseph D, Marini Joan C, Caird Michelle S, Morris Michael D, Kozloff Kenneth M
Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan Ann Arbor, MI, USA.
Department of Chemistry, University of Michigan Ann Arbor, MI, USA.
Bone. 2016 Mar;84:222-229. doi: 10.1016/j.bone.2016.01.001. Epub 2016 Jan 6.
Bone composition and biomechanics at the tissue-level are important contributors to whole bone strength. Sclerostin antibody (Scl-Ab) is a candidate anabolic therapy for the treatment of osteoporosis that increases bone formation, bone mass, and bone strength in animal studies, but its effect on bone quality at the tissue-level has received little attention. Pre-clinical studies of Scl-Ab have recently expanded to include diseases with altered collagen and material properties such as osteogenesis imperfecta (OI). The purpose of this study was to investigate the role of Scl-Ab on bone quality by determining bone material composition and tissue-level mechanical properties in normal wild type (WT) tissue, as well as mice with a typical OI Gly➔Cys mutation (Brtl/+) in type I collagen. Rapidly growing (3-week-old) and adult (6-month-old) WT and Brtl/+ mice were treated for 5weeks with Scl-Ab. Fluorescent guided tissue-level bone composition analysis (Raman spectroscopy) and biomechanical testing (nanoindentation) were performed at multiple tissue ages. Scl-Ab increased mineral to matrix in adult WT and Brtl/+ at tissue ages of 2-4wks. However, no treatment related changes were observed in mineral to matrix levels at mid-cortex, and elastic modulus was not altered by Scl-Ab at any tissue age. Increased mineral-to-matrix was phenotypically observed in adult Brtl/+ OI mice (at tissue ages>3wks) and rapidly growing Brtl/+ (at tissue ages>4wks) mice compared to WT. At identical tissue ages defined by fluorescent labels, adult mice had generally lower mineral to matrix ratios and a greater elastic modulus than rapidly growing mice, demonstrating that bone matrix quality can be influenced by animal age and tissue age alike. In summary, these data suggest that Scl-Ab alters the matrix chemistry of newly formed bone while not affecting the elastic modulus, induces similar changes between Brtl/+ and WT mice, and provides new insight into the interaction between tissue age and animal age on bone quality.
组织水平的骨成分和生物力学是决定全骨强度的重要因素。硬化蛋白抗体(Scl-Ab)是一种用于治疗骨质疏松症的促合成代谢疗法候选药物,在动物研究中,它可增加骨形成、骨量和骨强度,但其对组织水平骨质量的影响却很少受到关注。Scl-Ab的临床前研究最近已扩展到包括胶原和材料特性改变的疾病,如成骨不全症(OI)。本研究的目的是通过测定正常野生型(WT)组织以及I型胶原具有典型OI Gly➔Cys突变(Brtl/+)的小鼠的骨材料成分和组织水平力学性能,来研究Scl-Ab对骨质量的作用。快速生长(3周龄)和成年(6月龄)的WT和Brtl/+小鼠用Scl-Ab治疗5周。在多个组织年龄阶段进行荧光引导的组织水平骨成分分析(拉曼光谱)和生物力学测试(纳米压痕)。Scl-Ab在2-4周龄的成年WT和Brtl/+小鼠中增加了矿物质与基质的比例。然而,在皮质中部未观察到与治疗相关的矿物质与基质水平变化,并且在任何组织年龄阶段,Scl-Ab均未改变弹性模量。与WT相比,在成年Brtl/+ OI小鼠(组织年龄>3周)和快速生长的Brtl/+(组织年龄>4周)小鼠中,从表型上观察到矿物质与基质增加。在由荧光标记定义的相同组织年龄下,成年小鼠的矿物质与基质比例通常低于快速生长的小鼠,且弹性模量更大,这表明骨基质质量可受动物年龄和组织年龄的共同影响。总之,这些数据表明,Scl-Ab改变了新形成骨的基质化学性质,同时不影响弹性模量,在Brtl/+和WT小鼠之间诱导了相似的变化,并为组织年龄和动物年龄对骨质量的相互作用提供了新的见解。